Nigel Birks

Corporate Broking Director

Nigel joined Cavendish (then finnCap) in 2021 bringing with him a distinguished 30-year career in life sciences.

He led the No. 1 ranked Extel-rated research team at Dresdner Kleinwort, covering EU and US pharma, medtech and biotech companies, all the while executing multiple European and UK capital raises.

Prior to Cavendish, Nigel was at WG Partners advising UK, European and Australian life science companies on capital market transactions, managing institutional investor relationships and leading a team of four specialist sales.

Following his MBA in management, Nigel worked for Eli Lilly and subsequently ZS Associates, a US life science consultancy.